Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

Transplant International

Volumn 16, Issue 3, 2003, Pages 202-206

  Garcia, Valter Duro ^a   Bonamigo Filho, José Luz ^a   Neumann, Jorge ^a   Fogliatto, Laura ^a   Geiger, Anna Maria ^a   Garcia, Clotilde Druck ^a   Barros, Vivianne ^a   Keitel, Elizete ^a   Bittar, Antonio Eduardo ^a   Des Santos, Auri Ferrera ^a   Roithmann, Sergio ^a  

^a Santa Casa Complexo Hospitalar   (Brazil)

Author keywords

Post transplant lymphoproliferative disease; Rapamycin; Rituximab; Transplantation

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CD20 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; COUGHING; CYTOMEGALOVIRUS INFECTION; DRUG HYPERSENSITIVITY; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHUMAN; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; VIRUS INFECTION; WHEEZING;

ADOLESCENT; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037979084     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2003.tb00287.x     Document Type: Article

References (30)

1. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD (1999) Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 354:1698-1699
2. Dror Y, Greenberg M, Taylor G, Superina R, Hébert D, West L, Connolly B, Sena L, Allen U, Weitzman S (1999) Lymphoproliferative disorders after organ transplantation in children. Transplantation 67:990-998
3. Dumont FJ, Staruch MJ, Grammer T, Blenis J, Kastner CA, Rupprecht KM (1995) Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. Cell Immunol 163:70-79
4. Faller DV, Mentzer SJ, Perrine SP (2001) Induction of the Epstein-Barr thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus associated malignancies. Curr Opin Oncol 13:360-367
5. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E (1998) Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 352:1285
6. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C (1991) Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451
7. Grillo-Lopez AJ (2000) Rituximab: an insider's historical perspective. Semin Oncol 27:9-16
8. Grillo-Lopez AJ, Lynch J, Corffier B, Connors JM, Swinnen LJ (1999) Rituximab therapy of lymphoproliferative disorders in immunosuppressed patients. Abstract 662. VII International Conference on Malignant Lymphoma. Lugano, 2-5 June
9. Hanto DW, Frizzera G, Gajl-Peczalska K, Balfour HH, Simmons RL, Najarian JS (1985) Acyclovir therapy of Epstein-Barr virus induced post-transplant lymphoproliferative diseases. Transplant Proc 17:89-92
10. Harris NL, Ferry JA, Swerdlow SH (1997) Posttransplant lymphoproliferative disorders (PTLD): summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14:8-14
11. Knowles DM, Cesarman E, Chadburn A (1995) Correlative morphologic and molecular genetic analysis demonstrate three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552-558
12. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95:1502-1505
13. Leblond V, Dhedin N, Bruneel MFM, Choquet S, Hermine O, Porcher R, Quoc SN, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V (2001) Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19:772-778
14. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, Silberstein LE, Nowel PC, Schuler W, Shaw LM, Wask MA (2000) The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci 97:4285-4290
15. Milpied N, Antoine C, Garnier JL, Parquet N, Vasseur B, Bouscary D, Carret AS, Faye A, Quartier P, Bourbigot B, Bourquard P, Hurault de Ligny B, Reguerre Y, Stoppa AM, Dubief F, Mathieu-Boué A, Leblond V (2000) Humanized anti-CD20 monoclonal antibody (rituximab) in B posttransplant lymphoproliferative disorders: a retrospective analysis of 32 patients. Ann Oncol [Suppl 1]:113
16. Muthukkumar S, Ramesh TM, Bondada S (1995) Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60:264-270
17. Niedermeier J, Hoffmeyer F, Hertenstein B, Hoeper MM, Fabel H (2000) Treatment of lymphoproliferative disease with rituximab. Lancet 355:499
18. O'Dwyer ME, Launder T, Rabkin JM, Nichols CR (2000) Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab. Leuk Lymphoma 39:411-419
19. Oertel SHK, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB (2000) Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation. Transplantation 69:430-432
20. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermannn TM, Wiesner RH, Swinnen LJ, Woodle ES, Bromberg JS (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 68:1517-1525
21. Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo V, Casolari B (2001) Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody rituximab. Crit Rev Oncol Hematol 37:13-25
22. Seghal SN, Camardo JS, Scarola JA, Maida BT (1995) Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens 4:482-487
23. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683
24. Shapiro RS, Chauvenet A, McGuire W, Pearson A, Craft AW, McGlave P, Filipovich A (1988) Treatment of B-cell lymphoproliferative disorders with interferon-αand intravenous gammaglobulin. N Engl J Med 318:1334
25. Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE (1999). Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 68:1851-1854
26. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB (1995) Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55:1982-1988
27. Skoda-Smith S, Douglas VK, Mehta P, Graham-Pole J, Wingard JR (2001) Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and rituximab. Bone Marrow Transplant 27:329-332
28. Starzl TE (1968) Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula (in discussion of Murray JE, Wilson RE, Tylney NL). Ann Surg 168:416-435
29. Starzl TE, Penn I, Halgrimson CG (1970) Immunosuppression and malignant neoplasms. N Engl J Med 283:934-937
30. Younes BS, McDiarmid SV, Martin MG, Vargas JH, Gross JA, Busutt RW (2000) The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 70:94-99